lilly和MSD达成研究联合用药治疗多种肿瘤的协议

Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cance

Combinations of KEYTRUDA® (pembrolizumab) with Alimta® (pemetrexed), Cyramza® (ramucirumab), or necitumumab to be explored

KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSELY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials:

Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). This study is currently enrolling.
Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015.
Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015.
The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.

"Cancer is not one disease but rather more than 200 diseases, all of which have different causes and treatments," said Richard Gaynor, M.D., senior vice president, product development and medical affairs, Lilly Oncology. "Therefore research into combinations of immune-based therapies with other agents that could address these different tumor types is important. This collaboration between Lilly and Merck represents each company's strong commitment to patients fighting these devastating diseases."

"Our understanding of the immune system's role and its impact in the treatment of cancer continues to grow," said Eric Rubin, M.D., vice president, global clinical development, oncology, Merck Research Laboratories. "Collaborations such as this one are important in advancing the investigation of novel immuno-oncology combinations in different cancers, and to achieving our shared goal of bringing meaningful benefits to patients facing cancer."

礼来将联合默沙东研究PD-1抑制剂pembrolizumab与培美曲塞、ramucirumab和necitumumab的联合用药方案。

默克将会启动一项2期临床，联合pembrolizumab和培美一线应用于肺鳞癌患者，该临床已经开始入组
礼来将会启动一项多臂的1/2期临床，联合ramucirumab和pembrolizumab应用于多种肿瘤中，预计于2015年开始。
礼来将会启动一项1/2期临床，联合pembrolizumab和necitumumab应用于NSCLC患者中，预计于2015年开始。

source: https://investor.lilly.com/releasedetail.cfm?ReleaseID=890978

牛

关注